Tradestie Institutional Equity Comparison Engine
BBIO vs BHVN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BHVN Overall Edge
BHVN Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical while BBIO counters with relative strength in Options & Structure. Fundamentally, BBIO trades at N/M Forward P/E with -37.3% operating margin (+192.6% YoY revenue) versus BHVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BBIO sits in CONSOLIDATION (3rd %ile IV; Dealer Gamma Walls on Pro) against BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BBIO N/M vs BHVN N/M Fwd P/E
Growth & Margin Winner
BHVN
Op Margin -37.3% vs 0.0% ยท YoY +192.6% vs +0.0%
Momentum & Technical Winner
BHVN
1Y +19.3% vs +72.6% ยท 52W Pos 49% vs 59%
Options & Structure Winner
BBIO
CONSOLIDATION (3rd %ile IV) vs CONSOLIDATION (18th %ile IV)
BBIO
NASDAQ
BridgeBio Pharma, Inc. Common Stock
Pharmaceutical Preparations
$77.61
-0.89% 1D
Market Cap
$15.2B
1M Return
+16.89%
1Y Return
+19.28%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 19.0
Fund 40.0
Flow 66.0
Mom 40.0
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.95
+0.9% 1D
Market Cap
$2.1B
1M Return
+29.36%
1Y Return
+72.59%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BBIO +19.28%
BHVN +72.59%
Spread: +53.31 pp (BHVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BBIO TTM Op. Margin: -37.3%
BHVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BBIO vs BHVN. Trailing 12-month operating profitability (BBIO -37.3% vs BHVN 0.0%) and valuation multiples (BBIO N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BBIO | BHVN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.2B | $2.1B | Larger Scale | BBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +192.6% | +0.0% | Higher Growth | BBIO |
| Operating Margin (TTM) Profitability | -37.3% | 0.0% | Higher Margin | BHVN |
| Net Profit Margin Profitability | -59.8% | 0.0% | Higher Margin | BHVN |
| Return on Equity (ROE) Capital Efficiency | -1789.7% | -799.5% | Higher ROE | BHVN |
| 52-Week Range Position Momentum | 49% ($62โ$93) | 59% ($8โ$18) | Stronger Trend | BHVN |
| Beta / 30D Volatility Risk Regime | 0.87ฮฒ ยท 38% Vol | 1.40ฮฒ ยท 111% Vol | Lower Realized Risk | BBIO |
| Unified Institutional Score Composite Signal | 44.5 / 100 (HOLD) | 42.1 / 100 (HOLD) | Higher Composite | BBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BBIO vs BHVN Buy Guide
BBIO
CONSOLIDATION
91d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BBIO nor BHVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.